AlgoTherapeutix featured in Business Worldwide Magazine

AlgoTherapeutix – Developing novel treatments for pain control.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) has always been an iceberg in the ocean of cancer care.  Underestimated and heavily consequential. AlgoTherapeutix, an innovative Paris based biotech focused on complex pain may well melt the iceberg. 

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is an underestimated and devastating condition. Experienced by over 60 per cent of patients undergoing chemotherapy treatments, it ranks among the leading causes of chemotherapy modification or interruption, and is a cause of intense pain for patients.

A form of nerve damage to the skin of patients’ hands and feet, CIPN is most commonly associated with chemotherapies including platinum drugs, taxanes, vinca alkaloids (plant based drugs which block cell growth), proteasome inhibitors (drugs which prevent the degradation of protein within cells) and thalidomide derivatives used to stop cancer cells from developing).

The nerve damage caused by these chemotherapies produces symptoms which include burning, electric and stabbing sensations, numbness, tingling and allodynia – a condition which causes intense pain caused by normally painless stimuli.

Currently no FDA-approved therapy for CIPN exists. Despite the best efforts from their consultants, patients suffering from this crippling condition, have to endure severe pain and a reduced quality of life. “The debilitating pain which CIPN inflicts is not the only cause for concern. The condition often leads to chemotherapy dose reduction or termination, which may increase the chances of cancer-related morbidity and mortality,” explains Stéphane Thiroloix, CEO and Founder of AlgoTherapeutix.

To reduce the pain of the condition, clinicians will generally administer oral antidepressants and anticonvulsants. Whilst these yield some pain relief, they are limited and trigger taxing cardiovascular, neurological and neuromuscular side-effects. Indeed, reaching the right concentration in the skin requires the administration of high oral doses which in turn cause unwanted side-effects. 

Developing a novel solution

It is therefore logical to look for an active compound with strong peripheral activity that can be administered directly into the skin with minimal passage in the bloodstream and therefore cause minimal systemic side-effects. A few attempts occurred to design a topical presentation of amitriptyline – indeed amitriptyline’s activity has a strong peripheral activity. Those attempts failed and the scientific community since then considered that amitriptyline is too complex to formulate for topical administration, probably difficult to protect with solid Intellectual Property, and possibly exposed to pricing challenges once approved.

In 2018 AlgoTherapeutix, led by pharma veterans Stéphane Thiroloix (CEO) and Olivier Bohuon, commenced development of their own revolutionary treatment to relieve patients of the pain experienced by CIPN – ATX01. The distinctive concept behind this new treatment being that through targeting the epidermis and dermis – the outermost layers of skin and predominantly the location of damaged nerve fibres with a high concentration amitriptyline gel, ATX01 will achieve strong efficacy. By contrast, its expected low systemic absorption will avoid the side-effects of oral treatment. 

AlgoTherapeutix has now completed four vital stages of bringing ATX01 to market –

  1. Filing a solid patent portfolio;
  2. Applying formulation-by-design to develop a high-concentration formula with the intended penetration properties;
  3. Demonstrating the local activity of amitriptyline on the peripheral nervous system;
  4. Conducting a full pre-clinical plan which now makes ATX01 ready for testing on patients.

The innovative nature of ATX01 in revolutionising the administration of pain relief for chemotherapy and related treatments is undoubtedly due to the considerable knowledge and industry related experience of AlgoTherapeutix’ co-founders.  

A start up with a difference

In contrast to the typical start-up, AlgoTherapeutix was founded by Stéphane Thiroloix and Olivier Bohuon, who are both pharma veterans. Stephane’s career journey has included prestigious roles at reputable R&D-based pharmaceutical corporates, including Executive Vice-President of Corporate Development at Ipsen – a leading biopharmaceutical group dedicated to improving lies through innovative medicines in oncology, neuroscience and rare diseases.

Equally, Olivier Bohuon has served as Chief Executive and Vice President for established global corporates within the pharmaceutical sector, including Smith & Nephew and Abbott Laboratories. 

Backed by such illustrious expertise it is clear that AlgoTherapeutix’ innovative co-founders bring a wealth of top-to-bottom experience in the development, business development and commercialisation of pharmaceutical products. 

Discussing this, Stéphane Thiroloix said, “Awareness of our limits is our main quality, and we have the ability to reach out to experts to go beyond these limits. We will now see ATX01 through its clinical development, with an aim of teaming up with suitable pharma partners for a 2025 commercial launch.” 

From here, the door is open to exploring additional uses of ATX01, as its gel formulation and therefore simple method of administration may make it suitable for other forms of peripheral neuropathic pain. 

FDA designation

This has been evidenced with the FDA recently granting AlgoTherapeutix an Orphan Drug Designation to study ATX01 in erythromelalgia – (Formally known as Mitchell’s Disease) – a rare and extremely painful disorder which causes severe burning pain and inflammation of the hands and feet.

“The ability to investigate ATX01 in erythromelalgia is an exciting medical pursuit as sufferers have very few options for pain relief. This provides us with opportunity to increase our understanding of ATX01’s activity on essential pain conduction mechanisms” states Stéphane. 

Innovation can be measured on the dimensions of novelty and impact. Having challenged the consensus on CIPN and built a “silver start up” AlgoTherapeutix is likely to score highly on the impact scale when it brings genuine relief to millions of patients with CIPN and other forms of peripheral neuropathic pain.

Further information on Algo Therapeutix – this innovative Paris based biotech start up –  updated progress on ATX01 can be found at http://algotx.com/

source:

https://www.bwmonline.com/2020/08/17/algotherapeutix-developing-novel-treatments-for-pain-control/

FDA Grants ATX01 Orphan Drug Designation in Erythromelalgia

SURESNES, France- June 8th 2020 -(BUSINESS WIRE)–European biotech AlgoTherapeutix, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) has granted ATX01 (proprietary topical amitriptyline) Orphan Drug Designation for the treatment of erythromelalgia.

This designation is given to medications with the potential to treat rare conditions — those that affect fewer than 200,000 people in the U.S. Benefits include exemption from fees, financial incentives for clinical development, and seven years of market exclusivity if the treatment is approved.

Erythromelalgia is a rare condition that primarily affects the feet and less commonly the hands. It is characterized by intense, burning pain, severe redness and increased skin temperature either episodic or almost continuous. Whilst erythromelalgia is deemed to result from vasomotor abnormalities or dysfunction in the normal constriction and dilation of the caliber of certain blood vessels, the pain of erythromelalgia is thought to be associated with sodium channel dysfunction.

The ATX01 program primarily targets Chemotherapy-Induced Peripheral Neuropathy. Via topical administration of a proprietary high-concentration amitriptyline gel, ATX01 aims to directly reach the damaged nerve fibers in the skin and avoid the systemic side-effects of oral and injectable compounds. Pre-clinical investigation evidenced the anti-nociceptive activity of topical amitriptyline on voltage-gated sodium-channels Nav1.7, Nav1.8 and Nav1.9 and on peripheral sensory nerve fibers Aβ, A∂ and C. With its pre-clinical development complete, ATX01 will enter into Phase I clinical development in late 2020.

“The opportunity to investigate ATX01 in erythromelalgia is an exciting medical pursuit as those patients have very few options to relieve considerable pain. It provides us with an opportunity to further our understanding of ATX01’s activity on Nav1.7 in a pre-clinical and clinical setting”, says Stéphane Thiroloix, AlgoTherapeutix’s founder and CEO.

AlgoTherapeutix names Philippe Picaut Chief Scientific Officer

Philippe was previously Sr VP Neurosciences R&D at Ipsen, based in Cambridge (USA). He joins us with a large experience in R&D and business development, in particular in the field of neurology. Philippe is a pharmacist and his qualifications include an MSc in fundamental and applied toxicology, an MSc in anatomopathology, and a diploma of the American Board of Toxicology.

Philippe Picaut

Philippe brings a wealth of expertise as AlgoTherapeutix prepares to raise a Series A to launch ATX01 into clinical development for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

  • AlgoTherapeutix SAS
  • 49 rue des Nouvelles – 92150 Suresnes
  • Contact : contact@algotx.com

AlgoTx appoints Etienne Bienfait Fin&Admin Mgr.

As our growth accelerates and we embark on the Series A funding round for the clinical development of ATX01, there could be no better time for Etienne Bienfait to join AlgoTx as Manager of Finance an Administration.

Etienne Bienfait

Etienne holds a degree from the University Technical Institute (IUT) in Saint Nazaire and a Research Master in Management from Brest Business School. He has a strong track record in financial controlling at Covage and Bryan Garnier.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

  • AlgoTherapeutix SAS
  • 49 rue des Nouvelles – 92150 Suresnes
  • Contact : contact@algotx.com

Dr Emilio Garcia Quetglas appointed Chief Medical Officer of…

On October 1st 2019, AlgoTherapeutix appointed Dr Emilio Garcia Quetglas to the position of Chief Medical Officer of AlgoTherapeutix, in charge of the medical and clinical strategy and execution, as well as the scientific representation of AlgoTherapeutix towards external stakeholders. 

Emilo Garcia Quetglas.

Emilio is a Medical Doctor and a PhD specialized in Clinical Pharmacology. His clinical expertise is based on  18 years spent with patients at the University Clinic of Navarra, in departments of Clinical Pharmacology, Infectious Diseases, A&E, Pain and Cardiac Surgery, followed by 9 years in senior medical functions at Grünenthal, a leading pharmaceutical company in the field of pain. Emilio started as Medical Director, Innovation Therapeutics for Southern Europe, then extended his responsibilities to the whole of the EU, and since 2013 he was Sr Med Dir, Translational Science and Intelligence, Global Clinical Development. Among other projects, he played a significant part in the lifecycle management of lidocaine plaster, and tapentadol, and was the architect and builder of the PainSolve website which incorporates considerable expertise from KOL’s around the world.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact : contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com

Roy Freeman joins AlgoTherapeutix’s Scientific Advisory Board.

AlgoTherapeutix announced today the appointment of Prof Roy Freeman to its Scientific Advisory Board.

Roy Freeman, MD.

Roy Freeman is Professor of Neurology at the Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. 

His research and clinical interests are the physiology and pathophysiology of the small nerve fibers and the autonomic nervous system. His research encompasses the neurological complications of diabetes; neuropathic pain; the autonomic complications of Parkinson’s disease and multiple system atrophy; biomarkers in neurodegenerative diseases; and the diagnosis and treatment of autonomic and peripheral nervous system disorders. 

He has a special interest in clinical trial design in neuropathic pain in diabetic peripheral neuropathy and other peripheral nerve disorders. He has been principal investigator on many neuropathic pain clinical trials.  He is author of more than 200 original reports, chapters and reviews.

He is the principal investigator on National Institutes of Health-funded studies on the neurological complications of diabetes and biomarker development in alpha-synucleinopathies. 

Dr. Freeman is former chairman of the World Federation of Neurology research group on the autonomic nervous system, former president of the American Autonomic Society and former chairman of the Autonomic Section of the American Academy of Neurology.  He serves on the Executive Committee and the Steering Committee of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the United States FDA.  

He is Editor-in-Chief of Autonomic Neuroscience: Basic and Clinical and on the editorial boards of The Clinical Journal of Pain, Pain: Clinical Updates and Clinical Autonomic Research.

AlgoTherapeutix’ Scientific Advisory Board is chaired by Céline Greco (MD Phd), Hosp. Practitioner, Pain and Palliative Care Unit at the Hôpital Necker Enfants Malades in Paris. Céline heads up the Reference Center for Mastocytosis and Genetic Diseases with Cutaneous Expression. She is a laureate of the INSERM-Bettencourt school, and a Member of the Board  of the Council for Children Protection.

Roy Freeman joins the following members of the Scientific Advisory Board :

Philippe Arnaud, PharmD, is a Hospital Practitioner and Dpt Head at Bichat – Claude Bernard Hosp. He is a Professor at Paris Descartes Pharmacy & Biological Sciences University, and Erasmus teacher in Italy, Portugal and Canada. Philippe is a expert for the French National Medicines Agency (ANSM). 

Jean-François Bergmann is Professor of Therapeutics at Paris VII University. He headed up the Internal Medicine and Infectious Diseases Dpt at Hôpital Lariboisière, Paris. He is the President of the Medicines Committee of the Assistance Publique – Hôpitaux de Paris (AP-HP). He served as expert with the Drug Approval Committee and the Transparency Committee of the French National Medicines Agency (ANSM), and expert with the European Medicines Agency (EMA). 

Alain Eschalier is a pharmacist, a Medical Doctor and a Pharmacologist. He is Professor of Medical Pharmacology and former President of the Université d’Auvergne. Alain created and led several research units within INSERM and chairs the Analgesia Institute. 

Axel Le Cesne is Associate Professor of Medicine. Head of Medical Oncology Hospital Unit at Gustave Roussy, France. He headed the Bone/Soft Tissue Sarcoma Unit from 1995 to 2016. Axel is a member of ASCO, ESMO, EORTC Soft Tissue and Bone Sarcoma Group (STBSG). He served as Co-chair & Secretary of the French Sarcoma Group 2001-2005 and has been a member of the Board of Directors of the Connective Tissue Oncology Society since 2010. Axel is a member of French Academy of Medicine. 

Ronald Levy is Professor of Médecine, Stanford University Dpt of Oncology. He was awarded the Faisal International Prize, the Damashek Prize, the American Cancer Society’s Medal of Honor, the Leukemia and Lymphoma Society’s de Villiers Intl Achievement Award, the C. Chester Stock Award Memorial Sloan-Kettering Cancer Center, and the Karnofsky Award from the American Society of Clinical Oncology.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact- contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com

AlgoTherapeutix receives 0.5 M€ boost from BPIfrance.

Established in 2018 to develop topical treatments for complex pain, AlgoTherapeutix raised 2.6M€ last June towards the development of its lead program ATX01 in Chemotherapy-Induced Peripheral Neuropathy, and now gains further momentum from BPIfrance’s injection of 0.5 M€.

Supported by the European Union’s financial support via the Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI), this « PAI FEI » financing will enable AlgoTherapeutix to complete its pre-clinical program and initiate early clinical phases of ATX01’s development in CIPN.

Stéphane Thiroloix, President of AlgoTherapeutix, comments : « It is particularly encouraging that BPIfrance should validate our ambition precisely when we our pre-IND exchange with the FDA enables us to finalize a definitive development plan ».

Paris, Nov 20th 2019

AlgoTherapeutix raises 2.6M€ towards pre-clinical development of ATX01

One-year old AlgoTherapeutix (AlgoTx) announced it completed a 2.6M€ in Seed Capital. The French biotech start-up, hosted by the Paris Biotech Santé incubator is developing ATX01, a treatment for neuropathic pain caused by chemotherapy.

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet1: loss of sensitivity, tingling, cold and intense pain2can persist for months to years after treatment3,4. CIPN can prevent patients from walking or using their hands, thus deeply affecting their quality of life. 

CIPN is found in over two million patients each year in the US and Europe5,6, representing the first cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.

Promising exploratory data.

Inspired by clinical experience at a specialized pain treatment center, Algotx’s ATX01 targets topical treatment of CIPN by repositioning amitriptyline into a suitable formulation.

Early observations with the precursor of ATX01, published in January 2019 in Supportive Care in Cancer7 were the starting point of our development.

The completed Seeding Round enables AlgoTx to initiate the pre-clinical development of ATX01.

Strong human and entrepreneurial dynamics.

AlgoTx was founded in April 2018 by Stéphane Thiroloix and Olivier Bohuon, both seasoned professionals of the pharmaceutical world, where they developed solid strategic, operational, scientific and financial expertise in the companies they contributed to lead. Beyond ATX01, AlgoTx foresees the development of a portfolio of additional treatments for complex pain.

A strong operational team is gathered to execute the project, supported by a high-level Scientific Advisory Board and experienced Board of Directors.

After operating for a year in financial autonomy, in part thanks to support from BPIFrance, this Seed funding round enables Algotx to boost its activity. “Working on such a clinically relevant indication is a privilege and I am delighted with this strengthened financial support towards the development of ATX01, so it can become a reference treatment for chemotherapy-induced neuropathic pain”,Stephane Thiroloix, co-founder and President of AlgoTx comments.

Strong with an IP portfolio and solid pre-clinical data, ATX01’s next funding round will take place in early 2020, to fund clinical development.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact- contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com

Refrences :

  1. Kerckhove N, Collin A, Condé S,Chaleteix C, Pezet D and Balayssac D (2017) Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front. Pharmacol. 8:86.
  2. Kerckhove N, et al. Neuropathies périphériques chimio-induites : symptomatologie et épidémiologie. Bull Cancer (2018)
  3. Park, Susanna B., David Goldstein, Arun V. Krishnan, Cindy S-Y Lin, Michael L. Friedlander, James Cassidy, Martin Koltzenburg, et Matthew C. Kiernan. « Chemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis ». CA: A Cancer Journal for Clinicians63, no6 (novembre 2013): 419‑37. 
  4. Argyriou, Andreas, Athanasios Kyritsis, Thomas Makatsoris, et Haralabos Kalofonos. « Chemotherapy-Induced Peripheral Neuropathy in Adults: A Comprehensive Update of the Literature ». Cancer Management and Research, mars 2014, 135. 
  5. American Cancer Society. « Cancer Treatment & Survivorship Facts & Figures 2016-2017 », 2016.
  6. « Global Cancer Observatory ». 
  7. Rossignol, Julien, Benoit Cozzi, François Liebaert, Séverine Hatton, Marcel-Louis Viallard, Olivier Hermine, et Céline Greco. « High Concentration of Topical Amitriptyline for Treating Chemotherapy-Induced Neuropathies ». Supportive Care in Cancer, 4 janvier 2019. 

AlgoTherapeutix appoints Alain Eschalier and Axel Le Cesne to…

AlgoTherapeutix, a French Biotech developing ATX01 for the treatment of Chemotherapy-Induced Peripheral Neuropathy, announced on February 11th 2019 the appointment of Axel Le Cesne to its Scientific Advisory Board, followed by the appointment of Alain Eschalier on May 19th 2019.

Axel Le Cesne

Axel Le Cesne is Associate Professor of Medicine. Head of Medical Oncology Hospital Unit at Gustave Roussy, France. He headed the Bone/Soft Tissue Sarcoma Unit from 1995 to 2016. Axel is a member of ASCO, ESMO, EORTC Soft Tissue and Bone Sarcoma Group (STBSG). He served as Co-chair & Secretary of the French Sarcoma Group 2001-2005 and has been a member of the Board of Directors of the Connective Tissue Oncology Society since 2010. Axel is a member of French Academy of Medicine. 

Alain Eschalier

Alain Eschalier is a pharmacist, a Medical Doctor and a Pharmacologist. He is Professor of Medical Pharmacology and former President of the Université d’Auvergne. Alain created and led several research units within INSERM and chairs the Analgesia Institute. 

AlgoTherapeutix’ Scientific Advisory Board is chaired by Céline Greco (MD Phd), Hosp. Practitioner, Pain and Palliative Medicine Care Unit at the Hôpital Necker Enfants Malades in Paris. Céline heads up the Reference Center for Mastocytosis and genetic disease with cutaneous expression. She is a laureate of the INSERM-Bettencourt school, and a Member of the Board  of the Council for Children Protection.

Axel Le Cesne and Alain Eschalier join the following Members of the Scientific Advisory Board :

Ronald Levy is Professor of Médecine, Stanford University Dpt of Oncology. He was awarded the Faisal International Prize, the Damashek Prize, the American Cancer Society’s Medal of Honor, the Leukemia and Lymphoma Society’s de Villiers Intl Achievement Award, the C. Chester Stock Award Memorial Sloan-Kettering Cancer Center, and the Karnofsky Award from the American Society of Clinical Oncology.


Jean-François Bergmann is Professor of Therapeutics at Paris VII University. He headed up the Internal Medicine and Infectious Diseases Dpt at Hôpital Lariboisière, Paris. He is the President of the Medicines Committee of the Assistance Publique – Hôpitaux de Paris (AP-HP). He served as expert with the Drug Approval Committee and the Transparency Committee of the French National Medicines Agency (ANSM), and expert with the European Medicines Agency (EMA). 

Ivan Krakowski is medical oncology and pain specialist. He heads up the Oncology Supportive Care at Institut Bergonié, and is the President of AFSOS (French speaking society of supportive care in oncology). Ivan is a Board Member of the National Cancer Committee and serves on the Council of EU Cancerology Training School. He is the Co-editor of « Oncologie » & « Douleur& Analgésie”.

Philippe Arnaud, PharmD, is a Hospital Practitioner and Dpt Head at Bichat – Claude Bernard Hosp. He is a Professor at Paris Descartes Pharmacy & Biological Sciences University, and Erasmus teacher in Italy, Portugal and Canda. Philippe is a Member French National Medicines Agency (ANSM). 

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact- contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com

AlgoTherapeutix appoints Jean-François Labbé, Hugues Le Bret and Fabrice…

Paris, May 1st 2019

In order to strengthen its strategic and operational ability, AlgoTherapeutix appointed a new Board of Directors consisting of Jean-François Labbé (Chairman), Hugues le Bret and Fabrice Aurousseau as well as Stéphane Thiroloix, Founder and CEO of AlgoTherapeutix.

Jean-François Labbé

Jean-François Labbé (MBA), founded SpePharm Holding BV and was its CEO from 2006 to 2012. He was previously CEO of OTL Pharma SA from 2001 to 2004, COO of ProStrakan UK from 2004 to 2005, and Pdt of Parke-Davis France/ Warner-Lambert (Pfizer Group) from 1999 to 2001. Jean-François began his career at Hoechst Roussel in 1974, held GM positions in Europe, South Africa and the US. In 1995, he was appointed President, Europe Middle East Africa and member of the ExCom of Hoechst Marion Roussel until its merger with Aventis in 1999. He is a Board member at NicoxSA and Deinove, and served on the Board of Transgene.

Hugues Le Bret.

Hugues Le Bret is the Founder & Pdt of the Supervisory Board of Compte-Nickel since 2012. He became Adviser to the CEO of BNP Paribas in 2017 when the latter acquired Compte-Nickel. From 1999 to 2009 he was the Pdt & CEO of Boursorama, after being Dir of communication & ExCom member at Société Générale. Hugues started as an economy journalist in 1987, then worked at  Publicis for 3 years. He founded ABW in 1993, a financial communication company sold to Havas in 1996, and was then CEO of financial communication activities at Havas until 1999.

Board of Directors
Fabrice Aurousseau

Fabrice Aurousseau (IEP / Sc.Po, Master in Public Law), is the Co-Founder of the M&A Advisory firm Eponyme Partners, and the CEO & Co-founder of the R&D consulting firm PPRS Research. He served previously in activities of Corporate Finance at Compagnie Financière E. de Rothschild and BNP Paribas. 

Stéphane Thiroloix

Stéphane Thiroloix (HEC) is the Founder, President & CEO of AlgoTherapeutix. Stephane is the Chairman of the Board at Jellagen Marine Biotechnologies, and strategic advisor to Hoalen and Ythera. Prior to founding AlgoTherapeutix, Stephane served as CEO of Mayoly-Spindler (2014-2018), EVP Europe at Smith&Nephew (2012-2014), EVP Corporate Dvt at Ipsen (2007-2012), VP Europe & GM France at Bristol-Myers Squibb (2002-2007), VP Europe Business Dvt at GSK (1998-2002). Stephane started his career at Roussel Uclaf (HMR / Sanofi) and occupied central and affiliate leadership positions between 1987 and 1998.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact- contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com